DNAnexus raises $100M for a cloud-based analytics platform aimed at genomics and other clinical big data

DNAnexus raises $100M for a cloud-based analytics platform aimed at genomics and other clinical big data

4 years ago
Anonymous $-9GJQVHNr8

https://techcrunch.com/2020/06/09/dnanexus-raises-100m-for-a-cloud-based-analytics-platform-aimed-at-genomics-and-other-clinical-big-data/

DNAnexus, which provides a cloud platform for governments, universities, doctors, and pharmaceutical companies to tap into DNA and other clinical datasets and collaborate on scientific research projects, is today announcing a big step ahead in its efforts to grow its reach and purpose. The 10 year-old startup, originally spun out of Stanford’s school of medicine, has raised $100 million in funding.

The round, technically a Series G, is being co-led by Perceptive Advisors and Northpond Ventures (both specialist science and biotech investors), with participation also from previous backers GV (which has been around since almost the beginning), Foresite Capital, TPG Capital, and First Round Capital. DNAnexus is also picking up a new strategic backer in this round: Regeneron Pharmaceuticals — one of several companies currently working on antibody therapies for COVID-19 recovery.

DNAnexus raises $100M for a cloud-based analytics platform aimed at genomics and other clinical big data

Jun 9, 2020, 12:30pm UTC
https://techcrunch.com/2020/06/09/dnanexus-raises-100m-for-a-cloud-based-analytics-platform-aimed-at-genomics-and-other-clinical-big-data/ > DNAnexus, which provides a cloud platform for governments, universities, doctors, and pharmaceutical companies to tap into DNA and other clinical datasets and collaborate on scientific research projects, is today announcing a big step ahead in its efforts to grow its reach and purpose. The 10 year-old startup, originally spun out of Stanford’s school of medicine, has raised $100 million in funding. > The round, technically a Series G, is being co-led by Perceptive Advisors and Northpond Ventures (both specialist science and biotech investors), with participation also from previous backers GV (which has been around since almost the beginning), Foresite Capital, TPG Capital, and First Round Capital. DNAnexus is also picking up a new strategic backer in this round: Regeneron Pharmaceuticals — one of several companies currently working on antibody therapies for COVID-19 recovery.